TP53 and ovarian carcinoma: Our exploratory finding that TP53 mutations present at diagnosis became undetectable in cfDNA after chemotherapy but re-appeared at disease progression highlights the potential role of TP53 missense mutations as a biomarker for clinical disease monitoring in ovarian cancer.